DaVita Inc. (NYSE:DVA) is a leading provider of kidney care services in the United States, specializing in dialysis treatments for patients with chronic kidney failure. The company operates numerous outpatient dialysis centers and competes with other healthcare providers like Fresenius Medical Care in the dialysis market.
On October 29, 2025, DaVita is set to release its quarterly earnings, with analysts estimating an EPS of $3.17 and revenue of $3.43 billion. The company aims to leverage technology upgrades and cost management to boost performance. In the previous quarter, DaVita's EPS of $2.95 exceeded the Zacks Consensus Estimate by 9.3%, showcasing its ability to surpass expectations.
DaVita's focus on technology-driven productivity and value-based care is crucial in addressing challenges like high missed treatment rates and slow volume growth. Despite these hurdles, DaVita has consistently exceeded earnings estimates in three of the past four quarters, with an average surprise of 4.7%, as highlighted by Zacks.
Financially, DaVita's P/E ratio of 11.77 reflects the market's valuation of its earnings, while a price-to-sales ratio of 0.70 suggests a relatively low market valuation compared to revenue. The company's enterprise value to sales ratio of 1.62 and enterprise value to operating cash flow ratio of 11.48 provide insights into its valuation and cash flow efficiency.
DaVita's debt-to-equity ratio is notably negative at -34.67, indicating a unique capital structure. However, the company maintains a current ratio of 1.39, suggesting a solid liquidity position to cover short-term liabilities. With an earnings yield of 8.50%, DaVita offers a perspective on return on investment, highlighting its financial stability.
